After medical device M&A picked up last year, 2026 had a busy first quarter.
Abbott closed its $21 billion acquisition of cancer test maker Exact Sciences, concluding one of the largest medtech deals in recent years. Companies also announced other multibillion-dollar deals in the first quarter. Boston Scientific shared plans in January to buy Penumbra, a maker of thrombectomy and embolization devices, for $14.5 billion. Danaher revealed plans in February to buy patient monitoring firm Masimo.
Several medtech firms have also announced major divestitures in the past year. Some notable ones to watch include BD’s planned $17.5 billion sale of its biosciences and diagnostics businesses and Johnson & Johnson’s planned divestiture of its orthopedics segment. Meanwhile, Medtronic completed its spinoff of MiniMed, the medtech giant’s diabetes business.
Here are the top M&A deals so far this year:
